Publication
Unlocking the blockchain: Digitizing the insurance value chain - Chapter 2
Global | Publication | April 2017
An R3 and Norton Rose Fulbright white paper
Our global blockchain team has published a global legal and regulatory guide titled ‘Unlocking the blockchain’.
Overview
Interest in blockchain technologies has grown dramatically over the last twelve months.
This has triggered growth in investment in businesses operating in this area and marked engagement from all industry sectors (and financial institutions in particular) in blockchain technologies and their disruptive potential. Such engagement has led to the development of increasingly sophisticated proof-of-concept use cases and notable live deployments.
In view of these developments, we have produced a new global legal and regulatory guide to blockchain technologies in which we explore the regulatory considerations and a range of other legal issues that should be taken into account with any proposed deployment. The guide will be published in a series of chapters, with the first one covering ‘an introduction to blockchain technologies’ that we invite you to read.
Chapter 2: Digitizing the insurance value chain
Digitizing the insurance value chain through the use of blockchain and distributed ledger technologies (DLT) has the potential to revolutionise the insurance market, from the way insurance products are distributed, underwritten and administered, to the way the market is regulated.
Perhaps even more exciting than the benefits of digitizing the distribution chain is the potential for innovative new products and new business models to transform the industry. Much like the expansion of applications for the world wide web from two initial use cases at its launch - sending emails and file transfer - to the seemingly limitless use cases available today, distributed ledger technologies present a fertile ground for an explosion of innovation in the insurance industry.
When considering the use of these technologies, industry players will need to fully appreciate the challenges and risks. Any proposed deployment will need to take a broad range of legal and regulatory factors into consideration. In view of this, Norton Rose Fulbright, in association with R3, have produced a global legal and regulatory guide to DLT Use Cases in the Insurance Industry.
R3 is a leading consortium working with over 60 of the world’s largest financial institutions to develop ground-breaking commercial applications for the financial services industry that leverage the appropriate elements of distributed and shared ledger technology.
We invite you to read the first chapter which can be downloaded here. The subsequent chapters will only be available to contacts who have registered.
Chapters in the series:
Register to receive the subsequent chapters
Topics
- An introduction to blockchain technologies
- The IP and IT issues
- The regulatory considerations
- Litigation and dispute resolution considerations
- Competition / anti-trust issues
- Tax considerations
Use cases
- Digitizing the energy value chain
- Digitizing the insurance value chain
- Clearing and settlement
- Securitisation and trade receivables finance
- Identity (including data privacy issues)
- Supply chain management
- DAOs (decentralised autonomous organisations)
If you would like to discuss any aspect of this topic further, please get in touch.
Recent publications
Publication
The GCR Guide to Life Sciences – Product denigration
Marta Giner Asins and Arnaud Sanz of our Paris office are the authors of a chapter on product denigration that has been published in the third edition of the Global Competition Review’s The Guide to Life Sciences.
Publication
The GCR Guide to Life Sciences – Merger control: Procedural issues
Miranda Cole, Julien Haverals and Emma Clarke of our Brussels/ London offices are the authors of a chapter on procedural issues in merger control that has been published in the third edition of the Global Competition Review’s The Guide to Life Sciences. This covers a number of significant procedural developments that have affected merger review of life sciences transactions.
Subscribe and stay up to date with the latest legal news, information and events . . .